Chugai Pharmaceutical Co., Ltd. - Asset Resilience Ratio
Chugai Pharmaceutical Co., Ltd. (CUP0) has an Asset Resilience Ratio of 22.41% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Chugai Pharmaceutical Co., Ltd.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Chugai Pharmaceutical Co., Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €553.09 Billion | 22.41% |
| Total Liquid Assets | €553.09 Billion | 22.41% |
Asset Resilience Insights
- Good Liquidity Position: Chugai Pharmaceutical Co., Ltd. maintains a healthy 22.41% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Chugai Pharmaceutical Co., Ltd. Industry Peers by Asset Resilience Ratio
Compare Chugai Pharmaceutical Co., Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 5.03% |
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 7.18% |
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 10.04% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705 |
Drug Manufacturers - General | 5.75% |
|
Hunan Jingfeng Pharmaceutical
SHE:000908 |
Drug Manufacturers - General | 0.38% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Zhejiang Haisen Pharmaceutical Co. Ltd. A
SHE:001367 |
Drug Manufacturers - General | 32.14% |
Annual Asset Resilience Ratio for Chugai Pharmaceutical Co., Ltd. (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Chugai Pharmaceutical Co., Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 22.41% | €553.09 Billion | €2.47 Trillion | +1.75pp |
| 2024-12-31 | 20.66% | €456.14 Billion | €2.21 Trillion | +6.15pp |
| 2023-12-31 | 14.50% | €280.31 Billion | €1.93 Trillion | -0.52pp |
| 2022-12-31 | 15.03% | €280.94 Billion | €1.87 Trillion | +1.75pp |
| 2021-12-31 | 13.27% | €204.22 Billion | €1.54 Trillion | -- |
About Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal … Read more